Trial Profile

Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for Patients 60-75 Years of Age With Secondary AML

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Expanded access
Sponsors Celator Pharmaceuticals; Jazz Pharmaceuticals plc

Most Recent Events

04 Dec 2018 Results assessing safety of CPX-351 in patients with acute myeloid leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
28 Nov 2018 According to a Jazz Pharmaceuticals media release, data will be presented at the the 60th American Society of Hematology (ASH) Annual Meeting 2018.
17 Aug 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com